Claro Advisors’s ImmunityBio IBRX Stock Holding History

Claro Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10,000	Closed	-$18.2K	–	384
2023 Q1	$18.2K	Hold	10,000	–	–	0.01%	352
2022 Q4	$50.7K	Hold	10,000	–	–	0.02%	316
2022 Q3	$37K	Hold	10,000	–	–	0.01%	276
2022 Q2	$37K	Hold	10,000	–	–	0.01%	276
2022 Q1	$61K	Hold	10,000	–	–	0.02%	278
2021 Q4	$61K	Hold	10,000	–	–	0.02%	278
2021 Q3	$97K	Hold	10,000	–	–	0.04%	249
2021 Q2	$143K	Hold	10,000	–	–	0.06%	230
2021 Q1	$237K	Hold	10,000	–	–	0.12%	183
2020 Q4	$133K	Hold	10,000	–	–	0.07%	205
2020 Q3	$69K	Hold	10,000	–	–	0.04%	191
2020 Q2	$123K	Buy	+10,000	New	+$56.5K	0.08%	182

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return

Claro Advisors's IBRX Position: Q2 2023 in Review

Claro Advisors sold out of ImmunityBio (IBRX) in Q2 2023, closing a stake of 10,000 shares — an estimated $18.2K sold.

Claro Advisors first reported a position in IBRX in Q2 2020 and held it in 12 quarters. The position peaked at $237K in Q1 2021. 117 funds tracked by Wall St. Rank hold IBRX as of Q2 2023.

Claro Advisors reported no remaining ImmunityBio position as of Q2 2023 after selling out during the quarter.
Claro Advisors sold 10,000 ImmunityBio shares in Q2 2023, an estimated $18.2K.
Claro Advisors first reported a position in ImmunityBio in Q2 2020 and held it in 12 quarters.
Claro Advisors's ImmunityBio position peaked at $237K in Q1 2021.
117 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2023.

Based on Claro Advisors's 13F filing for Q2 2023, filed 8 Aug 2023.